Pemphigus foliaceus

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

Retrieved on: 
Wednesday, December 20, 2023
Biology, Patient, Efgartigimod alfa, Autoantibody, PV, Consistency, Literature, Pemphigus vulgaris, Conference call, Euronext, PD, Steroid, Pemphigus foliaceus, Growth, Safety, Immunoglobulin G

argenx will not pursue additional development in pemphigus and plans to prioritize clinical development of efgartigimod in its ongoing severe autoimmune indications.

Key Points: 
  • argenx will not pursue additional development in pemphigus and plans to prioritize clinical development of efgartigimod in its ongoing severe autoimmune indications.
  • “We are disappointed by today’s results, particularly for pemphigus patients who have seen little innovation in this treatment space,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx.
  • “We are grateful to the pemphigus community and all involved in the ADDRESS study, including patients, healthcare professionals, and our argenx teams,” continued Dr. Truyen.
  • Consistent pharmacodynamic (PD) effect of efgartigimod SC: Treatment with efgartigimod SC led to total immunoglobulin G (IgG) and desmoglein autoantibody (DSG-1 and DSG-3) reductions up to 75%.

Galderma and Children's Skin Disease Foundation Celebrate Decade-Long Partnership

Retrieved on: 
Thursday, June 30, 2022
Dermatology, Patient, Life, Vitiligo, Travel, Skin, Epidermolysis bullosa, CSDF, Ectodermal dysplasia, Sleepaway Camp, Awareness, Partnership, Nevoid basal-cell carcinoma syndrome, General manager, Ichthyosis, Instagram, Child, DRS, Pemphigus foliaceus, Family, Program, Multimedia, Education, Hospital, Medicine, Entertainment, Camp Wonder, Galderma, Cetaphil

FORT WORTH, Texas, June 30, 2022 /PRNewswire/ -- Galderma is entering its tenth year of partnership with Camp Wonder. Founded by the Children's Skin Disease Foundation (CSDF), Camp Wonder is a medically-staffed summer camp program for children ages 7 to 16 with serious skin diseases. Since beginning the partnership in 2012, Galderma and the CSDF have strived to elevate awareness of these critical skin conditions impacting countless children. To date, Galderma has donated more than $1.7 million and approximately 50,000 Cetaphil products to the Camp Wonder infirmary, along with supporting on the ground annually via company volunteers.

Key Points: 
  • Founded by the Children's Skin Disease Foundation (CSDF), Camp Wonder is a medically-staffed summer camp program for children ages 7 to 16 with serious skin diseases.
  • Since beginning the partnership in 2012, Galderma and the CSDF have strived to elevate awareness of these critical skin conditions impacting countless children.
  • They're such a unique partner in that they truly embody our organization's mission, and we've worked hand-in-hand to raise awareness of skin diseases that so often go undiscussed," said Francesca Tenconi, founder of the Children's Skin Disease Foundation.
  • "So many families affected by skin disease face heavy financial burdens so fundraising dollars truly make all the difference.

argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

Retrieved on: 
Thursday, May 19, 2022
Degenerative disease, Risk, No, Company, Pemphigus foliaceus, Annual general meeting, Neuromuscular Disorders, Immunoglobulin G, PV, Pemphigus vulgaris, Infection, Euronext, Patient, Biology, SID, Antibody, Quality of life, BP, Research, Journal of the American Academy of Dermatology, FC, Instagram, IIP, Breda, Neutrophil, Lymphocyte, Monocyte, Skin, LinkedIn, Twitter, Recurrent corneal erosion, Society, Acantholysis, Red blood cell, Pharmaceutical industry, Vaccine, Cell, Neonatal Fc receptor, Dermatology, Pemphigus, Pemphigus

The novel translational data, along with previously published translational data in Cells , will also be presented in a symposium today at the Society for Investigative Dermatology (SID) Annual Meeting at 7:30am PT.

Key Points: 
  • The novel translational data, along with previously published translational data in Cells , will also be presented in a symposium today at the Society for Investigative Dermatology (SID) Annual Meeting at 7:30am PT.
  • Efgartigimod is being investigated in several autoimmune diseases known to be mediated by disease-causing IgG antibodies, including neuromuscular disorders, blood disorders, and skin blistering diseases.
  • argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases.
  • The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises.

Brutons Tyrosine Kinase (BTK) Inhibitors Drug Pipeline Market Report 2022: Comprehensive Insights About 30+ Companies and 30+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 10, 2022
Health, Pharmaceutical, Mantle cell lymphoma, Chronic lymphocytic leukemia, Patient, Food, BTK, Pemphigus, Waldenström's macroglobulinemia, B-cell lymphoma, Shanda, Clinical trial, ITP, Bruton's tyrosine kinase, Adult, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Technology, FDA, Pemphigus foliaceus, Pemphigus vulgaris, Waldenström, European Commission, Acquisition, NDA, BeiGene, Lymphocytosis, Degenerative disease, Inhibitor, Discovery, News, Royal commission, II, Pharmaceutical industry

This "Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape.

Key Points: 
  • This "Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape.
  • A detailed picture of the Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape is provided which includes the disease overview and Brutons Tyrosine Kinase (BTK) Inhibitors treatment guidelines.
  • Brutons Tyrosine Kinase (BTK) Inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Brutons Tyrosine Kinase (BTK) Inhibitors drugs segregated based on following parameters that define the scope of the report.
  • The companies which have their Brutons Tyrosine Kinase (BTK) Inhibitors drug candidates in the most advanced stage, i.e.

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in CIDP

Retrieved on: 
Tuesday, November 16, 2021
People, Immunoglobulin therapy, Safety, Drug development, Peripheral nervous system, Myositis, Immunoglobulin G, Chronic inflammatory demyelinating polyneuropathy, Private Securities Litigation Reform Act, Plasmapheresis, Degenerative disease, Health, SAN, U.S. Securities and Exchange Commission, Neuromuscular Disorders, Infection, NASDAQ, Myasthenia gravis, Coronavirus, Risk, MG, Autoimmune disease, COVID-19, Forward-looking statement, Fatigue, PV, GLOBE, PF, Antibody, Pemphigus vulgaris, INCAT, Muscle weakness, Time, Prevalence, Patient, Pemphigus foliaceus, ITP, CIDP, Adult, Pharmaceutical industry, Vaccine

The ADHERE trial is a registrational, prospective, multi-center study to investigate the safety and efficacy ofweekly subcutaneous (SC) efgartigimod in adult patients with CIDP.

Key Points: 
  • The ADHERE trial is a registrational, prospective, multi-center study to investigate the safety and efficacy ofweekly subcutaneous (SC) efgartigimod in adult patients with CIDP.
  • Diagnosis of CIDP will be confirmed by an independent panel of experts prior to enrollment into Stage A.
  • In Stage B, patients are randomized to either SC efgartigimod or placebo for up to 48 weeks.
  • The primary endpoint is event-driven and based on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) overall disability score.

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Pemphigus

Retrieved on: 
Monday, November 15, 2021
Torso, Prednisone, Safety, Drug development, Myositis, Immunoglobulin G, Chronic inflammatory demyelinating polyneuropathy, Private Securities Litigation Reform Act, Degenerative disease, Scalp, Phase 3, Health, SAN, U.S. Securities and Exchange Commission, Neuromuscular Disorders, Pemphigus foliaceus, Infection, NASDAQ, Immune system, Myasthenia gravis, Coronavirus, Risk, Blister, MG, COVID-19, Itch, Face, Forward-looking statement, Rituximab, Patient, Pain, GLOBE, PF, Antibody, Pemphigus vulgaris, Mouth, Ulcer, Skin, Prevalence, Top of the Form (quiz show), ITP, CIDP, Fine chemical, Pharmaceutical industry, Vaccine

ADDRESS is a randomized, double-blind, placebo-controlled, multi-center trial evaluating the safety and efficacy of efgartigimod in approximately 150 patients with PV or PF.

Key Points: 
  • ADDRESS is a randomized, double-blind, placebo-controlled, multi-center trial evaluating the safety and efficacy of efgartigimod in approximately 150 patients with PV or PF.
  • We are excited about the therapeutic potential of efgartigimod in pemphigus, based on its mode of action in clearing IgGs.
  • We look forward to advancing the China portion of this registrational Phase 3 study and to bringing such an innovative treatment option to patients with pemphigus in China.
  • Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase 2 multicentre, open-label feasibility trial.

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune Thrombocytopenia

Retrieved on: 
Thursday, November 11, 2021
Immunoglobulin therapy, Quality of life, Safety, Drug development, Myositis, Immunoglobulin G, Chronic inflammatory demyelinating polyneuropathy, Private Securities Litigation Reform Act, Degenerative disease, Health, Splenectomy, SAN, U.S. Securities and Exchange Commission, Neuromuscular Disorders, Pemphigus foliaceus, Infection, NASDAQ, Disease, Immune system, Myasthenia gravis, Coronavirus, Risk, MG, COVID-19, SC, Intracerebral hemorrhage, Forward-looking statement, Neonatal Fc receptor, PV, Rituximab, GLOBE, PF, Antibody, Pemphigus vulgaris, Autoantibody, Bruise, Patient, Bleeding, Prevalence, ITP, CIDP, Adult, Pharmaceutical industry, Vaccine

The company announced today that the first patient with primary immune thrombocytopenia (ITP) was treated with efgartigimod in Greater China (mainland China, Hong Kong, Macau, and Taiwan) as part of the global registrational ADVANCE-SC Phase 3 study.

Key Points: 
  • The company announced today that the first patient with primary immune thrombocytopenia (ITP) was treated with efgartigimod in Greater China (mainland China, Hong Kong, Macau, and Taiwan) as part of the global registrational ADVANCE-SC Phase 3 study.
  • Also, efgartigimod appears to be well tolerated, potentially because of its unique structure and ability to bind to the FcRn receptor.
  • The prevalence of primary ITP in Greater China is estimated at 120,000 patients.
  • Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.

Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus

Retrieved on: 
Thursday, September 9, 2021

The Phase 3 study, which is the first placebo-controlled trial of a BTK inhibitor in pemphigus, enrolled adult patients with moderate-to-severe pemphigus vulgaris or pemphigus foliaceus.

Key Points: 
  • The Phase 3 study, which is the first placebo-controlled trial of a BTK inhibitor in pemphigus, enrolled adult patients with moderate-to-severe pemphigus vulgaris or pemphigus foliaceus.
  • We are committed to investigating rilzabrutinib further and progressing our clinical programs forward to deliver new treatment options for patients.
  • Currently options for the treatment of pemphigus (including pemphigus vulgaris and pemphigus foliaceus) are limited and systemic corticosteroid treatment remains the standard of care.
  • Rilzabrutinib is being investigated in a Phase 3 trial for the treatment of immune thrombocytopenia, a rare blood disorder, and in a Phase 2 study for the autoimmune condition IgG4-related disease.